Pacer Advisors
ARQT icon

Pacer Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Pacer Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35K Buy
+1,349
New +$31.4K ﹤0.01% 2123
2024
Q3 		– Sell
-1,476
Closed -$13.7K – 2571
2024
Q2 		$13.7K Sell
1,476
-2,399
-62% -$21.7K ﹤0.01% 3499
2024
Q1 		$38.4K Buy
+3,875
New +$28.9K ﹤0.01% 3275
2021
Q2 		– Sell
-887
Closed -$26K – 1419
2021
Q1 		$26K Sell
887
-184
-17% -$5.75K ﹤0.01% 1492
2020
Q4 		$30K Buy
+1,071
New +$26.2K ﹤0.01% 1460

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Pacer Advisors's ARQT Position: Q2 2026 in Review

Pacer Advisors opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 1,349 shares worth $35K. The stake represents ﹤0.01% of the portfolio and ranks #2123 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in ARQT as recently as Q2 2024.

Pacer Advisors first reported a position in ARQT in Q4 2020 and has held it in 5 quarters since. The position peaked at $38.4K in Q1 2024. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Pacer Advisors held 1,349 shares of Arcutis Biotherapeutics worth $35K as of Q2 2026.
  • Arcutis Biotherapeutics was a new Pacer Advisors position in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2123 holding.
  • Pacer Advisors first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 5 quarters since.
  • Pacer Advisors's Arcutis Biotherapeutics position peaked at $38.4K in Q1 2024.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.